In addition, we aimed to construct a risk model to predict Alzheimer’s continuum (A + T ± N ±) in normal elders (A-T-N-) based on the ATN research framework that diagnoses AD with biomarker evidence of Aβ (A), pathological tau (T), and FDG PET evidence of neurodegeneration or neuronal injury (N). This evidence concerns the gene MAPT and Alzheimer disease.